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Sir,
We thank Drs Maraqa and Lansdown for providing us with an
opportunity to clarify concerns about the generalisability and
validity of the findings in our recently published article on
heterogeneity of breast cancer risk factors by tumour character-
istics in a population-based study conducted in Poland (Garcia-
Closas et al, 2006). We are confident that the fundamental
conclusions of our study are valid and can be generalised to most
other Western populations for the reasons outlined below.
The authors note that the percentage of oestrogen receptor (ER)-
negative tumours in our study population was higher than in most
other Western populations. The percentage of ER-negative
tumours in the Polish population for all tumour types combined
was 34% (the figure of 41% quoted by Maraqa and Lansdown was
for ductal NOS tumours only), compared to 23% reported in the
Surveillance, Epidemiology and End Results (SEER) in the US for
the years of 2000–2002 and a similar age range as in our report
(Surveillance, 2005). There are several possible explanations for
this apparent difference. First, the relatively low percentage of
women having screening mammography in Poland compared to
other Western populations, such as the UK or US, probably led to
greater underdetection of slow-growing indolent ER-positive
tumours compared with ER-negative tumours. Second, criteria
for distinguishing weakly ER-positive from ER-negative tumours
vary, and in countries like the US, there is a tendency to favour
characterisation of weakly positive tumours as ER positive, to
provide more women options for tamoxifen treatment (Harvey
et al, 1999). Finally, exposures that might increase the risk of ER-
positive tumours, such as high body mass index among
postmenopausal women (Althuis et al, 2004), were less common
in the Polish population than in other countries such as the US.
Respectively, the percentage of women who were overweight
(X25kg/m
2) among white non-Hispanics in the US (Flegal et al,
2002) and Polish study subjects were 49 vs 22% for 20–39 year
olds, 61 vs 36% for 40–59 year olds and 66 vs 40% among those 60
or older.
The primary goal of our report was to assess the modification of
the associations between aetiologic exposures and breast cancer
risk by tumour subtypes, using a novel statistical approach to
account for correlated tumour characteristics, including
hormone receptor status. Our results were generally consistent
with previous studies, thus providing support for both the validity
and generalisability of our conclusions. Although our estimates
of overall relative risk for exposures that are modified by ER
status are valid, we recognise that they may differ from those
found in populations with a lower percentage of ER-negative
tumours. It was notable that the direction and magnitude of
overall associations of most aetiologic exposures and breast
cancer risk in Poland were similar to previously published
reports, with the exception of obesity among postmenopausal
women, which has been linked to greater risk for ER-positive
as compared to ER-negative tumours in many studies (Althuis
et al, 2004).
Our analyses also utilised standard statistical approaches to
adjust for correlated risk factors. Although residual confounding is
always possible, the contention that associations may have been
biased by a failure to account for factors correlated with
mammographic screening (e.g., education, HRT use) would not
apply. As shown in Table 1 of our report, there were some
differences in prior screening proportions between the cases and
controls (62 vs 54%), which are likely to reflect increased reporting
by cases of recent mammograms performed for breast cancer
symptoms.
Finally, concerns were also expressed regarding potential
error with histologic classifications in our study. The levels
of agreement between Polish and US pathology results for
the classification of ductal (80%) and lobular (68%) tumours
were similar to what would be expected in comparable reviews
in other settings, and the main disagreements were for the
classification of mixed tumours (18%), largely attributable to
differences in terminology. The US review was performed to
afford maximal opportunities for exploring aetiologic
relationships, whereas the Polish review was performed for
clinical management. Accordingly, the US review applied
stringent criteria for classifying tumours as pure ductal or
lobular carcinomas, placing more tumours in the mixed
category. Inclusion of cases without the US review could
have diluted differences between ductal and lobular tumours,
but should not have created differences had they not been
present. Published online 3 October 2006
*Correspondence: Dr M Garcia-Closas; Email: montse@nih.gov
British Journal of Cancer (2006) 95, 1302–1303
& 2006 Cancer Research UK All rights reserved 0007– 0920/06 $30.00
www.bjcancer.comREFERENCES
Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP,
Sherman ME (2004) Etiology of hormone receptor-defined breast cancer:
a systematic review of the literature. Cancer Epidemiol Biomarkers Prev
13: 1558–1568
Flegal KM, Carroll MD, Ogden CL, Johnson CL (2002) Prevalence
and trends in obesity among US adults, 1999–2000. JAMA 288:
1723–1727
Garcia-Closas M, Brinton LA, Lissowska J, Chatterjee N, Peplonska B,
Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A,
Zatonski W, Blair A, Kalaylioglu Z, Rymkiewicz G, Mazepa-Sikora D,
Kordek R, Lukaszek S, Sherman ME (2006) Established breast cancer
risk factors by clinically important tumour characteristics. Br J Cancer
95: 123–129
Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor
status by immunohistochemistry is superior to the ligand-binding assay
for predicting response to adjuvant endocrine therapy in breast cancer.
J Clin Oncol 17: 1474–1481
Surveillance (2005) Epidemiology and End Results SEER Program. Public-
Use Database (1973–2002), National Cancer Institute, DCCPS, Surveil-
lance Research Program, Cancer Statistics Branch, released April 2005,
based on the November 2004 submission. (accessed at www.seer.
cancer.gov)
Letter to the Editor
1303
British Journal of Cancer (2006) 95(9), 1302–1303 & 2006 Cancer Research UK